![April Manness](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
April Manness formerly worked at Luminor Medical Technologies, Inc., as Chief Financial Officer, Luminor Medical Technologies, Inc., as Chief Financial Officer in 2011, Kane Biotech, Inc., as Interim Chief Financial Officer from 2011 to 2012, and DiaMedica Therapeutics, Inc., as Chief Financial Officer.
Tidigare kända positioner av April Manness
| Företag | Position | Slut |
|---|---|---|
| KANE BIOTECH INC. | Finansdirektör/CFO | 2012-01-01 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Finansdirektör/CFO | 2011-12-23 |
| DIAMEDICA THERAPEUTICS INC. | Finansdirektör/CFO | - |
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Finansdirektör/CFO | 2007-10-17 |
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
4
Första gradens relationer
3
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 3 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Commercial Services |
Kane Biotech, Inc.
 Kane Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that manufactures animal health oral care products | Commercial Services |
DiaMedica Therapeutics, Inc.
 DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
